Shares of Lipocine Inc (NASDAQ:LPCN) have been assigned a consensus recommendation of “Hold” from the five analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $17.33.
Several analysts have issued reports on LPCN shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Lipocine in a research report on Friday, December 8th. Canaccord Genuity reaffirmed a “hold” rating and issued a $2.00 price objective (down previously from $11.00) on shares of Lipocine in a research report on Tuesday, January 9th. Finally, Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $11.00 price target on shares of Lipocine in a research report on Thursday, January 11th.
Several hedge funds have recently added to or reduced their stakes in LPCN. Goldman Sachs Group Inc. acquired a new stake in shares of Lipocine during the second quarter worth approximately $300,000. Ameriprise Financial Inc. grew its position in shares of Lipocine by 18.2% during the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after buying an additional 24,000 shares in the last quarter. Prosight Management LP acquired a new stake in shares of Lipocine during the fourth quarter worth approximately $1,283,000. Finally, Vanguard Group Inc. grew its position in shares of Lipocine by 39.7% during the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after buying an additional 155,110 shares in the last quarter. 17.46% of the stock is owned by institutional investors and hedge funds.
Shares of Lipocine (NASDAQ LPCN) traded up $0.13 during trading hours on Tuesday, reaching $1.70. 880,371 shares of the company’s stock traded hands, compared to its average volume of 768,744. Lipocine has a one year low of $1.15 and a one year high of $5.33. The firm has a market capitalization of $36.03, a P/E ratio of -1.77 and a beta of -0.94.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/19/brokerages-set-lipocine-inc-lpcn-price-target-at-17-33.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.